Isis Pharmaceuticals ISIS
-
ISIS Pharmaceuticals Management Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)
ISIS Pharmaceuticals , Inc. ( ISIS ) Bank of America Merrill Lynch Health Care Conference May ..... href='http://seekingalpha.com/article/1438351- isis - pharmaceuticals -management-presents-at-bank-of-america-merrill …
-
New Morningstar Analyst Report for Biogen Idec Inc
… midstage neurology and immunology pipeline is bolstered by strong collaborations (like the spinal muscular atrophy program through Isis ) as well as products with novel targets (like anti-LINGO for MS). At the end of 2012, Biogen had roughly $3.7 billion …
-
Isis Pharmaceuticals Slides A Little Despite Strong Earnings
By StockBaller : Isis Pharmaceuticals ( ISIS ) is a pharmaceutical company that has had quite a wide range ..... almost double Q3 2012 earnings. A graphical representation of ISIS ' earnings over the past 5 quarters (not including its most …
-
Isis Pharmaceuticals's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Isis Pharmaceuticals , Inc. ( ISIS ) Q1 2013 Earnings Conference Call May 7, 2013 16:30 pm ET ..... href='http://seekingalpha.com/article/1412641- isis - pharmaceuticals -s-ceo-discusses-q1-2013-results-earnings …
-
Even more from Isis Pharmaceuticals ( ISIS ) following earnings: The company announces a 9M share public offering. The deal's underwriters will have the option to buy an additional 1.35M shares. (PR)
Even more from Isis Pharmaceuticals ( ISIS ) following earnings : The company announces a 9M share public offering. The deal's underwriters will have the option to buy an additional 1.35M shares. ( PR ) Post your comment!
-
More on Isis Pharmaceuticals' ( ISIS ) Q1 earnings: Revenues miss but results show Y/Y improvement on milestone payments of $7.5M from GlaxoSmithKline (Phase 2/3 ISIS -TTR) and $25M from Genzyme (NDA ...
More on Isis Pharmaceuticals ' ( ISIS ) Q1 earnings : Revenues miss but results show Y/Y improvement on milestone payments of $7.5M from GlaxoSmithKline ( Phase 2/3 ISIS -TTR) and $25M from Genzyme ( NDA filing ) — more milestone …
-
Isis Pharmaceuticals ( ISIS ): Q1 EPS of $-0.02 (in line). Revenue of $43.4M misses by $1.84M. (PR)
Isis Pharmaceuticals ( ISIS ): Q1 EPS of $-0.02 (in line). Revenue of $43.4M misses by $1.84M . ( PR ) Post your comment!
-
Regulus Therapeutics: Strong Balance Sheet As It Moves Into Clinical Development
… targeting small regulatory RNAs called microRNAs, is a joint venture between two leading RNA therapeutics companies, Isis ( ISIS ) and Alnylam ( ALNY ). Last fall, Regulus joined its two parent companies on the NASDAQ stock exchange after an …
-
Isis Pharmaceuticals ([[ ISIS ]] +8.4%) enjoys a strong session after BMO reiterates its Outperform rating and raises its price target to $31 from $22 citing a meeting with the company's SVP of ...
Isis Pharmaceuticals ( ISIS +8.4% ) enjoys a strong session after BMO reiterates its Outperform ..... meeting with the company's SVP of Clinical Development regarding ISIS ' antisense oligonucleotide pipeline. Separately, ISIS renews its …
-
5 Biotechnology Stocks That Greatly Outperformed The Market In Q1
By Brian Nichols : In the first quarter of 2013, the NASDAQ Composite rose 8%. It was the only of the three major indexes that did not reach all-time highs. Although the NASDAQ is still far from reaching its all-time highs, an 8% return is still considered a positive. While many individual sectors